Clinical trials: Previously Treated Non Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
This is a study for patients with previously-treated advanced non-small cell lung cancer (NSCLC). The study will evaluate the safety of adding an investigational drug, MK-3475 to standard treatment with gemcitabine.
- Trial name
- NCT02422381
- Testing
- MK-3475, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Providence Health & Services
Lung Cancer
Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy
This research trial studies prognostic and predictive markers in patients with early stage non-small cell lung cancer receiving chemotherapy.
- Trial name
- NCT01294280
- Testing
- Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 241 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Carcinoma, Non-Small-Cell Lung
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery.
- Trial name
- NCT06012435
- Testing
- sigvotatug vedotin, docetaxel
- Where
- 331 sites in United States, Argentina and 23 more
- Volunteers
- 762 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Non-small Cell Lung Cancer
Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the anti-tumor activity of LY2181308 in combination with docetaxel compared to docetaxel alone in participants with non-small cell lung cancer who were previously treated with first line…
- Trial name
- NCT01107444
- Testing
- Docetaxel, LY2181308
- Where
- 36 sites in United States, Belgium and 4 more
- Volunteers
- 180 people
- Sponsor
- Eli Lilly and Company
Non-squamous Non-small-cell Lung Cancer
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
To evaluate the efficacy of tiragolumab with atezolizumab and bevacizumab in previously-treated advanced non-squamous NSCLC.
- Trial name
- NCT04958811
- Testing
- Tiragolumab, Atezolizumab, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Georgetown University
Advanced Cancer, Metastatic Cancer
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
- Conditions
- Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
- Trial name
- NCT05853575
- Testing
- Adagrasib
- Where
- 98 sites in United States, Brazil and 16 more
- Volunteers
- 200 people
- Sponsor
- Mirati Therapeutics Inc.
NSCLC, Non-small Cell Lung Cancer
Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer
This is a phase 2, open-label study to evaluate the efficacy and safety of combination of Apatinib and Fluzoparib with or without Adebrelimab in previously-treated TP53-mutant advanced non-small cell lung cancer.
- Trial name
- NCT05932264
- Testing
- Apatinib + Fluzoparib, Apatinib + Fluzoparib + Adebrelimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. This study focuses on two types of cancers: Acute Myeloid Leukemia (AML) and Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer, Cancer
- Trial name
- NCT04272203
- Testing
- ABBV-184
- Where
- 17 sites in United States, France and 3 more
- Volunteers
- 14 people
- Sponsor
- AbbVie
Lung Cancer
Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01124669
- Testing
- DNA analysis, mutation analysis, laboratory biomarker analysis
- Volunteers
- 80 people
- Sponsor
- ECOG-ACRIN Cancer Research Group